A detailed history of Geode Capital Management, LLC transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 961,309 shares of VERA stock, worth $36.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
961,309
Previous 782,716 22.82%
Holding current value
$36.5 Million
Previous $12 Million 244.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$14.91 - $49.14 $2.66 Million - $8.78 Million
178,593 Added 22.82%
961,309 $41.5 Million
Q4 2023

Feb 13, 2024

BUY
$9.29 - $16.0 $410,144 - $706,384
44,149 Added 5.98%
782,716 $12 Million
Q3 2023

Nov 13, 2023

BUY
$13.71 - $19.64 $1.2 Million - $1.73 Million
87,875 Added 13.5%
738,567 $10.1 Million
Q2 2023

Aug 11, 2023

BUY
$6.11 - $17.83 $1.04 Million - $3.04 Million
170,647 Added 35.55%
650,692 $10.4 Million
Q1 2023

May 15, 2023

BUY
$5.41 - $18.3 $1.21 Million - $4.08 Million
222,979 Added 86.74%
480,045 $3.73 Million
Q4 2022

Feb 13, 2023

BUY
$15.74 - $22.19 $271,766 - $383,132
17,266 Added 7.2%
257,066 $4.97 Million
Q3 2022

Nov 14, 2022

BUY
$13.27 - $22.31 $467,263 - $785,579
35,212 Added 17.21%
239,800 $5.11 Million
Q2 2022

Aug 12, 2022

BUY
$12.82 - $23.4 $26,165 - $47,759
2,041 Added 1.01%
204,588 $2.78 Million
Q1 2022

May 13, 2022

BUY
$17.8 - $28.06 $1.44 Million - $2.27 Million
80,965 Added 66.59%
202,547 $4.76 Million
Q4 2021

Feb 11, 2022

BUY
$15.01 - $35.8 $750,109 - $1.79 Million
49,974 Added 69.79%
121,582 $3.25 Million
Q3 2021

Nov 12, 2021

BUY
$13.71 - $30.6 $761,343 - $1.7 Million
55,532 Added 345.43%
71,608 $1.24 Million
Q2 2021

Aug 13, 2021

BUY
$11.5 - $19.97 $184,874 - $321,037
16,076 New
16,076 $213,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.03B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.